A nasal spray is a delivery route, not a safety category. The route can change absorption, local effects and how reliably a product reaches its target. A compound studied by injection or in cultured cells cannot be assumed to have the same effects when placed in a nasal formulation.

Approved desmopressin nasal products provide a concrete example: their prescribing information includes important safety warnings, including hyponatremia. The existence of an approved nasal peptide therefore demonstrates both that the route can be useful and that it requires product-specific evaluation. Desmopressin nasal spray prescription label

The formulation and device matter

A nasal product includes the active ingredient, other components, container and spray characteristics. These affect the delivered product. A label stating the amount in a bottle does not establish consistency between sprays or stability during use.

Claims of direct delivery to the brain also need evidence for the particular formulation and outcome. A proposed transport mechanism is not proof of meaningful brain exposure or a clinical benefit in people.

Route-specific evidence should remain route-specific

FDA’s peptide safety discussions identify uncertainties for particular substances and routes. Such distinctions are lost when an article treats every nasal peptide as equivalent or assumes that avoiding a needle removes systemic risk. FDA safety concerns for nominated compounding substances

A good research review records how the product was delivered, what exposure was measured and whether the study evaluated the intended clinical outcome. It should also identify what is known about local tolerability and longer-term use.

AXON does not supply nasal preparation recipes, spray calculations or self-administration instructions. The useful conclusion is that route, device and formulation are part of the evidence. A convenient presentation cannot substitute for clinical data or make an unapproved research material equivalent to a regulated nasal medicine.